Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Compressed SPEEDER Technology for 3D Exams On 1.5T MR, Enabling High-speed MR Imaging Now FDA Approved

December 21, 2020

Compressed SPEEDER technology for 3D exams has been FDA-cleared for 3D sequences on Canon Medical Systems USA, Inc.’s Vantage Orian 1.5T MR system, so clinicians can easily expect to scan at least twice as fast, and even faster in many clinical scenarios*.

Compressed SPEEDER 3D** boosts MRI scan times during 3D sequences for exams such as surgical planning and orthopedic applications by reconstructing full resolution images from under-sampled data through iterative reconstruction. The innovative technique overcomes many of the limitations inherent to traditional parallel imaging and allows for greater acceleration. The system can even further accelerate exams with Fast3D, a new technique that can be used in combination with Compressed SPEEDER 3D to help make exams even quicker.

Compressed SPEEDER technology is available as an option in an all-new new version of M-Power software for the Vantage Orian 1.5T, which is also available with Fat Fraction Quantification**, an application integrated directly onto the system’s console to help clinicians image and quantify fatty liver disease. The application acquires six MR echoes at once, allowing for quick diagnoses, detailed severity grading, disease monitoring and treatment response, all in alignment with QIBA standards.

“With 30 percent of the U.S. population suffering from Fatty Liver Disease, the ability to diagnose quickly as well as quantify and monitor the disease has become extremely important to clinicians. Our Fat Fraction Quantification is an ideal solution, and it is on our Vantage Orian 1.5T console so that it can be integrated into existing workflow,” said Jonathan Furuyama, managing director, MR Business Unit, Canon Medical Systems USA, Inc.

Furuyama concluded, “At Canon Medical, our priority is to support our customers and their patients by providing them with timely advancements that can impact their outcomes and workflow. With the help of Compressed SPEEDER for 3D exams along with Fat Fraction Quantification, healthcare providers can offer a quick and comfortable experience for their patients.”


* Actual acceleration factors vary by case. Maximum acceleration factor is up to 16 times.

** Compressed SPEEDER 3D and Fat Fraction Quantification are both optional. Fat Fraction Quantification is FI-Quant.

Vantage Orian and Made for life are trademarks of Canon Medical Systems.

SourceCanon
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy